• Joint Development Agreement with the candy producer in Q1
• Progression in several projects, funding risk remains
• Our model implies a fair valuation of SEK 7.60 per share

A quiet final quarter of 2023 was followed by an eventful start of 2024 for Lund-based Bioextrax. In January, the American startup terminated the contract due to financial issues. For Bioextrax, the financial impact of the cancellation was limited according in our valuation model. However, the stock market reaction on the news was harsh sending the share price down by 30 per cent.

The initial research report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://twitter.com/vhcorp_se)